Skip to main content
Erschienen in: Intensive Care Medicine 2/2007

01.02.2007 | News

Clinical research in Italy in adult patients unable to consent: after implementation of the European Union's Directive 2001/20/CE

verfasst von: Christian J. Wiedermann, Mauro Almici, Salvatore Mangione, Antonello Giarratano, Oswald Mayr

Erschienen in: Intensive Care Medicine | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Excerpt

The European Union's Directive 2001/20/CE (“the Clinical Trials Directive”) was intended to simplify and harmonize the regulation of clinical trials across the EU and had to be implemented in member states by May 2004 [1]. It makes “good clinical practice” a legal requirement in the EU, and all clinical research is to be subjected to the same rigorous standards including protection of trial subjects. Some of these requirements, however, may be seen additional burden and a brake to clinical research in Europe [2, 3, 4, 5, 6, 7]. …
Literatur
1.
Zurück zum Zitat Anonymous (2001) Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Off J Eur Communities L121:34–44 Anonymous (2001) Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Off J Eur Communities L121:34–44
2.
Zurück zum Zitat Hemminki A, Kellokumpu-Lehtinen PL (2006) Harmful impact of EU clinical trials directive. BMJ 332:501–502PubMedCrossRef Hemminki A, Kellokumpu-Lehtinen PL (2006) Harmful impact of EU clinical trials directive. BMJ 332:501–502PubMedCrossRef
3.
Zurück zum Zitat Heidenreich K, Moritz A, Loffler H, Oberle-Rolle B (2005) Clinical trials in Germany and in the EU in the new legislative environment. An analysis from the industry's point of view. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 48:415–422PubMedCrossRef Heidenreich K, Moritz A, Loffler H, Oberle-Rolle B (2005) Clinical trials in Germany and in the EU in the new legislative environment. An analysis from the industry's point of view. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 48:415–422PubMedCrossRef
4.
Zurück zum Zitat Baeyens AJ (2004) Impact of the European Clinical Trials Directive on academic clinical research. Med Law 23:103–110PubMed Baeyens AJ (2004) Impact of the European Clinical Trials Directive on academic clinical research. Med Law 23:103–110PubMed
5.
Zurück zum Zitat Grienenberger A (2004) Establishing pan-European clinical trials: regulatory compliance and other practical considerations. J Biolaw Bus 7:58–63 Grienenberger A (2004) Establishing pan-European clinical trials: regulatory compliance and other practical considerations. J Biolaw Bus 7:58–63
6.
Zurück zum Zitat Stocchetti N, Dearden M, Karimi A, Lapierre F, Maas A, Murray GD, Ohman J, Persson L, Servadei F, Trojanowski T, Unterberg A (2004) New European directive on clinical trials: implications for traumatic head injury research. Intensive Care Med 30:517–518PubMedCrossRef Stocchetti N, Dearden M, Karimi A, Lapierre F, Maas A, Murray GD, Ohman J, Persson L, Servadei F, Trojanowski T, Unterberg A (2004) New European directive on clinical trials: implications for traumatic head injury research. Intensive Care Med 30:517–518PubMedCrossRef
7.
Zurück zum Zitat Druml C, Singer EA (2004) The European Directive: a further blow to science in intensive care medicine in Austria. Intensive Care Med 30:335PubMedCrossRef Druml C, Singer EA (2004) The European Directive: a further blow to science in intensive care medicine in Austria. Intensive Care Med 30:335PubMedCrossRef
8.
Zurück zum Zitat Liddell K, Chamberlain D, Menon DK, Bion J, Kompanje EJ, Lemaire F, Druml C, Vrhovac B, Wiedermann CJ, Sterz F (2006) The European Clinical Trials Directive revisited: the VISEAR recommendations. Resuscitation 69:9–14PubMedCrossRef Liddell K, Chamberlain D, Menon DK, Bion J, Kompanje EJ, Lemaire F, Druml C, Vrhovac B, Wiedermann CJ, Sterz F (2006) The European Clinical Trials Directive revisited: the VISEAR recommendations. Resuscitation 69:9–14PubMedCrossRef
9.
Zurück zum Zitat Liddell K, Kompanje EJ, Lemaire F, Vrhovac B, Menon DK, Bion J, Chamberlain D, Wiedermann CJ, Druml C; Working Group of the Vienna Initiative to Save European Academic Research (2006) Recommendations in relation to the EU clinical trials directive and medical research involving incapacitated adults. Wien Klin Wochenschr 118:183–191PubMedCrossRef Liddell K, Kompanje EJ, Lemaire F, Vrhovac B, Menon DK, Bion J, Chamberlain D, Wiedermann CJ, Druml C; Working Group of the Vienna Initiative to Save European Academic Research (2006) Recommendations in relation to the EU clinical trials directive and medical research involving incapacitated adults. Wien Klin Wochenschr 118:183–191PubMedCrossRef
10.
Zurück zum Zitat Lemaire F, Bion J, Blanco J, Damas P, Druml C, Falke K, Kesecioglu J, Larsson A, Mancebo J, Matamis D, Pesenti A, Pimentel J, Ranieri M; ESICM Task Force on Legislation Affecting Clinical Research in the Critically Ill Patient (2005) The European Union Directive on Clinical Research: present status of implementation in EU member states' legislations with regard to the incompetent patient. Intensive Care Med 31:476–479PubMedCrossRef Lemaire F, Bion J, Blanco J, Damas P, Druml C, Falke K, Kesecioglu J, Larsson A, Mancebo J, Matamis D, Pesenti A, Pimentel J, Ranieri M; ESICM Task Force on Legislation Affecting Clinical Research in the Critically Ill Patient (2005) The European Union Directive on Clinical Research: present status of implementation in EU member states' legislations with regard to the incompetent patient. Intensive Care Med 31:476–479PubMedCrossRef
11.
Zurück zum Zitat Geisler I, Hofmann HP, Nickel L (2005) Harmonisation of regulatory requirements for clinical trials on medicinal products for human use in the Directive 2001/20/EC and complementary guidance. Implementation of the 12th law amending the German drug law. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 48:141–146PubMedCrossRef Geisler I, Hofmann HP, Nickel L (2005) Harmonisation of regulatory requirements for clinical trials on medicinal products for human use in the Directive 2001/20/EC and complementary guidance. Implementation of the 12th law amending the German drug law. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 48:141–146PubMedCrossRef
12.
Zurück zum Zitat Silverman HJ, Druml C, Lemaire F, Nelson R (2004) The European Union Directive and the protection of incapacitated subjects in research: an ethical analysis. Intensive Care Med 30:1723–1729PubMedCrossRef Silverman HJ, Druml C, Lemaire F, Nelson R (2004) The European Union Directive and the protection of incapacitated subjects in research: an ethical analysis. Intensive Care Med 30:1723–1729PubMedCrossRef
13.
Zurück zum Zitat Cohen AF (2003) European guideline for the quality of non-commercial clinical trials: elegant implementation in the Netherlands via the amended Dutch medical research involving human subjects act. Ned Tijdschr Geneeskd 147:1493–1495PubMed Cohen AF (2003) European guideline for the quality of non-commercial clinical trials: elegant implementation in the Netherlands via the amended Dutch medical research involving human subjects act. Ned Tijdschr Geneeskd 147:1493–1495PubMed
14.
Zurück zum Zitat Singer EA, Mullner M (2002) Implications of the EU directive on clinical trials for emergency medicine. BMJ 324:1169–1170PubMedCrossRef Singer EA, Mullner M (2002) Implications of the EU directive on clinical trials for emergency medicine. BMJ 324:1169–1170PubMedCrossRef
15.
Zurück zum Zitat Tomino C (2005) Osservatorio Nazionale sulla Sperimentazione Clinica dei medicinali. 3° Rapporto Nazionale—2004. Agenzia Italiana del Farmaco, Rome, pp 16–29 Tomino C (2005) Osservatorio Nazionale sulla Sperimentazione Clinica dei medicinali. 3° Rapporto Nazionale—2004. Agenzia Italiana del Farmaco, Rome, pp 16–29
16.
Zurück zum Zitat Torbica A, Fattore G (2005) The “Essential levels of care” in Italy: when being explicit serves the devolution of powers. Eur J Health Econ [Suppl]:46–52 Torbica A, Fattore G (2005) The “Essential levels of care” in Italy: when being explicit serves the devolution of powers. Eur J Health Econ [Suppl]:46–52
Metadaten
Titel
Clinical research in Italy in adult patients unable to consent: after implementation of the European Union's Directive 2001/20/CE
verfasst von
Christian J. Wiedermann
Mauro Almici
Salvatore Mangione
Antonello Giarratano
Oswald Mayr
Publikationsdatum
01.02.2007
Verlag
Springer-Verlag
Erschienen in
Intensive Care Medicine / Ausgabe 2/2007
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-006-0458-1

Weitere Artikel der Ausgabe 2/2007

Intensive Care Medicine 2/2007 Zur Ausgabe

Tipps für den Umgang mit Behandlungsfehlern

01.05.2024 DGIM 2024 Kongressbericht

Es ist nur eine Frage der Zeit, bis es zu einem Zwischenfall kommt und ein Behandlungsfehler passiert. Doch wenn Ärztinnen und Ärzte gut vorbereitet sind, schaffen es alle Beteiligten den Umständen entsprechend gut durch diese Krise. 

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.